Monocarboxylate transporter�1 is an independent prognostic factor in esophageal squamous cell carcinoma

Abstract

The monocarboxylate transporter 1 (MCT1) has been reported to have significant prognostic value in several solid tumors. The present study aimed to explore its clinical significance in esophageal squamous cell carcinoma (ESCC). After acquiring and analyzing MCT1 (solute carrier family 16 member; SLC16A1) mRNA expression in The Cancer Genome Atlas (TCGA) database, the prognostic potential of MCT1 was assessed by immunohistochemistry (IHC). The impact of the knockdown of MCT1 by shRNA was evaluated using Cell Counting Kit-8 (CCK-8) and colony formation assays to determine whether MCT1 suppression affected the proliferation and survival of ESCC cells. MCT1 expression was found to correlate with T stage (P=0.005), N stage (P=0.036) and TNM stage (P= 0.035). Kaplan-Meier survival analysis showed that patients in a high-MCT1 group had a lower overall survival (OS) (P<0.001) and lower progression-free survival (PFS) (P<0.001). The results of univariate and multivariate Cox regression analyses demonstrated that MCT1 is an independent prognostic factor for OS (P= 0.001 and 0.01) and PFS (P=0.001 and 0.012). Downregulation of MCT1 suppressed proliferation and survival of ESCC cells in vitro. The proliferation rate and colony numbers were decreased in the sh-MCT1 groups (all P<0.05). Downregulation of MCT1 suppressed VEGF expression (all P<0.05). MCT1 may act as a biomarker for ESCC to identify patients with poor outcomes.

Clinicopathological and prognostic involvements of MCT1, MCT4 and IL7R in esophageal squamous cell carcinoma

“…Analysis from previous investigations concerning MCT1 in cancers, regardless of different types [19][20][21][22], revealed that MCT1 prevailed or predominantly over-expressed in cancerous tissues as compared with normal controls and up-regulated MCT1 was found to be linked with poor outcome as well as tumor metastases, which was fully in agreement with our observations in ESCC of our own case. What's congruent with our description with regard to MCT1 is that, in a recent study [18] by Chen X and colleagues, MCT1 was exhibited to be an independent prognostic factor in ESCC. What's different from the study by Chen X et al [18] in that, there was short of functional analysis data of MCT1 in our setting with cell culture system.…”

“…What's congruent with our description with regard to MCT1 is that, in a recent study [18] by Chen X and colleagues, MCT1 was exhibited to be an independent prognostic factor in ESCC. What's different from the study by Chen X et al [18] in that, there was short of functional analysis data of MCT1 in our setting with cell culture system. Examination of data from these aforementioned literatures along with our own findings about MCT1 in ESCC, explicitly suggested the prognostic value of MCT1 in malignancies, irrespective of their types.…”

“…In stark contrast, physiologically, MCT4 was found to be in charge of efflux of lactate, as systemically reviewed by Halestrap AP [16]. Although extensive studies can be readily available regarding the MCT1 in cancers of different types; it has been little described in esophageal cancer with the exception of two recent related reports [17,18]: one about MCT1 expression in Barrett's esophagus and adenocarcinoma, the other ESCC. Analysis from previous investigations concerning MCT1 in cancers, regardless of different types [19][20][21][22], revealed that MCT1 prevailed or predominantly over-expressed in cancerous tissues as compared with normal controls and up-regulated MCT1 was found to be linked with poor outcome as well as tumor metastases, which was fully in agreement with our observations in ESCC of our own case.…”

Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma

“… 4 Recent research has identified H3 methylation and monocarboxylate transporter 1 and Jumonji-domain containing 3 expression as biomarkers for the poor prognosis of ESCC. 18 – 20 Additionally, patients with higher C-reactive protein levels and neutrophil-to-lymphocyte ratios have a better prognosis after chemotherapy. 21 In this study, the clinicopathological characteristics, including sex, age, pathologic stage, G differentiation, and lesion sites, were not significantly correlated with the prognosis of patients with ESCC.…”

RAD001 targeted HUVECs reverses 12‐lipoxygenase‐induced angiogenesis in oesophageal squamous cell carcinoma

“…Western blot analysis was performed as previously described. 32 The membranes were exposed with an enhanced chemiluminescence reaction (ECL) kit, and the grey levels of the protein bands were analysed using the ImageJ 1.47v software. The sources of the primary antibodies applied were as follows:…”